Key facts: Eli Lilly Q4 2025 sales soar 43% to $19.3B; joins TrumpRx
I'm PortAI, I can summarize articles.
Eli Lilly's Q4 2025 earnings revealed a 43% sales rise to $19.3 billion, surpassing forecasts. The company expects 2026 revenue of $81.5 billion and adjusted EPS of $34.25.1Eli Lilly is joining the TrumpRx initiative, providing discounted cash prices on around 40 drugs, allowing consumers to buy medications directly at lower prices with a TrumpRx coupon.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments